Ardelyx, Inc. filings document a commercial-stage biopharmaceutical company with U.S. product revenue from IBSRELA and XPHOZAH and development activity centered on tenapanor and NHE3 inhibition. Form 8-K reports cover quarterly operating results, preliminary product sales, cash and investment updates, Regulation FD presentation materials, and other material-event disclosures tied to the company’s commercial and clinical programs.
Ardelyx proxy materials describe annual meeting proposals, director elections, say-on-pay matters, auditor ratification, executive compensation, board structure, and stockholder voting mechanics. Additional current reports record officer appointments, executive transitions, transition and separation agreements, compensatory arrangements, governance matters, and disclosure controls relevant to the company’s public-company reporting obligations.
ARDELYX, INC. filed an initial ownership report for Chief Legal Officer Felecia Ettenberg. The filing shows direct ownership of 237,000 shares of Common Stock.
It also reports a stock option to buy 355,000 shares of Common Stock at an exercise price of $6.30 per share, expiring on April 20, 2036. According to the vesting schedule, 25% of the option vests on April 20, 2027, with the remaining shares vesting in 36 equal monthly installments if her employment continues. Footnotes further note restricted stock units that convert into one share of Common Stock for each unit upon vesting.
ARDELYX, INC. President & CEO Michael Raab exercised stock options and sold shares in a planned transaction. He exercised options for 20,834 shares of common stock at an exercise price of $0.99 per share, then sold 41,668 common shares at a weighted average price of $6.2867 per share pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025. After these transactions, he holds 1,795,614 shares directly, plus additional indirect holdings of 24,364 and 1,000 shares held in family trusts.
ARDELYX, INC. Chief Medical Officer Dinavahi Rajani reported her equity holdings in connection with a Form 3 filing. She holds stock options to purchase 301,000 shares of Common Stock at an exercise price of $6.11 per share, expiring on April 1, 2036.
She also directly holds 201,000 shares of Common Stock. The option grant vests over time, with 25% of the shares vesting on April 1, 2027 and the remainder vesting in 36 equal monthly installments thereafter, subject to her continued employment or service with the company.
Ardelyx Inc received an amended Schedule 13G/A from The Vanguard Group reporting that, following an internal realignment, Vanguard and its subsidiaries/ divisions will report holdings separately. The filing states amount beneficially owned: 0 and percent of class: 0% as of 03/13/2026.
The amendment cites SEC Release No. 34-39538 (January 12, 1998) and explains that certain Vanguard subsidiaries that formerly were reported under The Vanguard Group, Inc. will now report on a disaggregated basis. The signing official is Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
ARDELYX, INC. President & CEO Michael Raab exercised stock options to acquire 20,833 shares of common stock at $0.99 per share, then sold 41,666 shares at a weighted average price of $5.84 per share under a pre-arranged Rule 10b5-1 trading plan.
After these transactions, he held 1,816,448 common shares directly and 374,168 stock options of this award, plus indirect holdings of 24,364 and 1,000 shares through family trusts for his children.
ARDELYX, INC. President & CEO Michael Raab reported option exercises and share sales in ARDX. He exercised stock options for 20,833 shares of common stock at an exercise price of $0.99 per share through a derivative conversion. The resulting 20,833 common shares were acquired and then partially offset by an open-market sale of 41,666 common shares at a weighted average price of $6.255 per share, executed in multiple trades between $6.08 and $6.56. The sale was made under a Rule 10b5-1 trading plan adopted on November 7, 2025. After these transactions, Raab directly held 1,836,153 common shares, with additional shares held indirectly through family trusts for his children.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting proposed sales of common stock tied to exercises and restricted stock units. The notice lists proposed sales of 83,333 shares on 02/24/2026 (exercise of stock options) and 83,333 shares from restricted stock units with a grant date of 02/19/2024. The filing also discloses a sale by Michael G. Raab of 45,982 shares on 02/20/2026 for $268,840.52.
Ardelyx director David M. Mott reported an open-market purchase of 333,333 shares of Ardelyx common stock. The weighted average purchase price was $5.839 per share, with individual trades executed between $5.67 and $6.00 per share. Following this transaction, he reports ownership of 3,302,918 shares, which includes 87,566 shares he holds for the benefit of entities associated with New Enterprise Associates, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
ARDELYX, INC. officer John E. Bishop reported automatic sales of company common stock tied to the vesting of restricted stock units. On February 20, 2026, a total of 3,179 shares of common stock were sold in several open-market transactions at prices between $5.70 and $5.87 per share. According to the footnote, these were automatic “sell-to-cover” transactions executed solely to cover withholding taxes due upon RSU vesting, rather than discretionary sales. After these tax-related sales, Bishop directly held 339,151 shares of Ardelyx common stock.
ARDELYX, INC. executive Joseph James Reilly reported open-market sales of 4,991 shares of common stock on February 20, 2026, at prices between $5.7003 and $5.865 per share. According to the footnote, these transactions were automatic sell-to-cover trades upon RSU vesting, executed solely to cover withholding taxes. After the sales, Reilly directly owned 151,790 Ardelyx shares.